Biological Psychiatry

Amygdala response to facial expressions in children and adults
pp. 309-316(8)
Authors: Thomas K.M.; Drevets W.C.; Whalen P.J.; Eccard C.H.; Dahl R.E.; Ryan N.D.; Casey B.J.

Noradrenergic dysfunction in the prefrontal cortex in depression: an [¹⁵O] H₂O PET study of the neuromodulatory effects of clonidine
pp. 317-325(9)
Authors: Fu C.H.Y.; Reed L.J.; Meyer J.H.; Kennedy S.; Houle S.; Eisfeld B.S.; Brown G.M.

[¹²³I] -CIT and single photon emission computed tomography reveal reduced brain serotonin transporter availability in bulimia nervosa
pp. 326-332(7)
Authors: Tauscher J.; Pirker W.; Willeit M.; de Zwaan M.; Bailer U.; Neumeister A.; Asenbaum S.; Lennkh C.; Praschak-Rieder N.; Brucke T.; Kasper S.

Haplotype study of three polymorphisms at the dopamine transporter locus confirm linkage to attention-deficit/hyperactivity disorder
pp. 333-339(7)
Authors: Barr C.L.; Xu C.; Kroft J.; Feng Y.; Wigg K.; Zai G.; Tannock R.; Schachar R.; Malone M.; Roberts W.; Nothen M.M.; Grunhage F.; Vandenbergh D.J.; Uhl G.; Sunohara G.; King N.; Kennedy J.L.

Drugs used in the treatment of attention-deficit/hyperactivity disorder affect postsynaptic firing rate and oscillation without preferential dopamine autoreceptor action
pp. 340-350(11)
Authors: Ruskin D.N.; Bergstrom D.A.; Shenker A.; Freeman L.E.; Baek D.; Walters J.R.

Chronic cold exposure potentiates CRH-evoked increases in electrophysiologic activity of locus coeruleus neurons
pp. 351-359(9)
Authors: Jedema H.P.; Finlay J.M.; Sved A.F.; Grace A.A.

Reactivity of serotonin in whole blood: relationship with drug response in obsessive-compulsive disorder
pp. 360-368(9)
Authors: Humble M.; Bejerot S.; Bergqvist P.B.F.; Bengtsson F.

Elevated motor threshold in drug-free, cocaine-dependent patients assessed with transcranial magnetic stimulation
pp. 369-373(5)
Authors: Boutros N.N.; Lisanby S.H.; Tokuno H.; Torello M.W.; Campbell D.; Berman R.; Malison R.; Krystal J.H.; Kosten T.

Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications
pp. 374-384(11)
Authors: Green M.F.; Braff D.L.

Sexually dimorphic relationship of a 5-HT_2A promoter polymorphism with obsessive-compulsive disorder
pp. 385-388(4)
Authors: Enoch M.-A.; Greenberg B.D.; Murphy D.L.; Goldman D.